_{A message from our friends at Stocks to Trader (Sponsor)}

A setup we're watching for Monday

Want to start next week off big?

Our new algorithm may have just uncovered an undervalued trade with a great chance of moving 2X or more this Monday.

...One ticker...

...One trade...

...One move...

All you have to do is make this one play on Monday.

While I can't promise future performance, previous picks from this new Monday Algo have racked up gains of +149%, +190%, and +536%... in as little as one day.

And we think this new pick could be just as big.

But if we're right, it may move...

So get the details now.

–Tim Sykes

_{BONUS ARTICLE}

The $100 Billion Pill Race: Why Big Pharma Is Panic-Buying Biotechs

This isn't just another biotech headline.

It's the start of a land grab.

Eli Lilly's reported $7.8 billion acquisition of Centessa (CNTA) just fired the starting gun on what looks like a full-blown GLP-1 M&A cycle.

And when big pharma starts writing checks like that…

It's usually not the last one.

Scoreboard: What Actually Happened

Let's simplify the setup:

Eli Lilly acquires Centessa for ~$7.8B
GLP-1 weight-loss drugs are now a $100B+ long-term market opportunity
Big pharma has:
- Massive cash piles
- Aging pipelines
- Urgent need for next-gen obesity treatments

Translation:

They're not buying because they want to.

They're buying because they have to.

The Real Reason This Is Happening

This is a classic scarcity trade.

Right now, the GLP-1 landscape is dominated by two giants:

Eli Lilly
Novo Nordisk

Everyone else?

Playing catch-up.

And here's the problem:

You can't build a competitive obesity drug pipeline overnight.

Clinical timelines are long.
Regulatory hurdles are real.
Success rates are low.

So what do you do if you're big pharma?

You buy it.

Deep Dive: The "Scarcity Value" Setup

This is where things get interesting for a Cheap Investor lens.

Because this isn't about dozens of targets.

It's about a limited pool of viable assets.

The key traits buyers are hunting:

Oral GLP-1 candidates (next-gen convenience)
Better tolerability profiles
Strong early-stage efficacy data
Scalable manufacturing potential

That list is short.

And when supply is limited—but demand is massive—

Prices move fast.

The Rising Star: Viking Therapeutics (VKTX)

If you're looking for the next domino, traders are already circling one name:

Viking Therapeutics (VKTX)

Why?

Strong data in obesity trials
Positioned in the GLP-1 / metabolic space
Still mid-cap relative to Lilly/Novo scale

This is exactly the kind of profile that gets attention in a cycle like this.

Not guaranteed.

But very much in play.

Is It Cheap?

Here's where discipline matters.

Biotech M&A cycles can create two types of "cheap":

1) Pre-takeout mispricing

Stocks that are undervalued relative to their pipeline potential

2) Post-hype momentum

Stocks that get bid up purely on speculation

Right now, VKTX is walking that line.

The bullish argument:

Scarcity + strong data = potential premium buyout

The cautious take:

A lot of that narrative may already be getting priced in

Bull / Base / Bear

Bull Case

More deals follow Lilly's move
VKTX or similar names get acquired at a premium
GLP-1 market expands faster than expected

→ Biotech multiples re-rate higher

Base Case

Selective M&A continues
Only the strongest pipelines get bought
Stocks trade on data + speculation

→ Volatility, but opportunity remains

Bear Case

M&A slows after initial deals
Clinical data disappoints
Valuations outrun fundamentals

→ "Takeout premium" fades quickly

Action Plan for the Cheap Investor

This is not a spray-and-pray biotech trade.

You want to be selective.

Focus on:

Clinical data quality
Pipeline differentiation
Positioning within GLP-1 ecosystem

Avoid:

Pure speculation without data
Chasing spikes on takeover rumors

Cheap Investor Checklist

Track these signals:

Additional GLP-1 acquisitions
Viking Therapeutics trial updates
Oral GLP-1 developments
Big pharma pipeline gaps
Regulatory milestones
Sector-wide valuation shifts

Bottom Line

This is not just a biotech rally.

It's a scarcity-driven acquisition cycle.

Big pharma needs growth.
GLP-1 is the prize.
And there aren't many credible players left to buy.

That's why deals are happening.

Disclaimer: This editorial is for informational purposes only and should not be considered investment advice. Always conduct independent research before making financial decisions.

_{IMPORTANT NOTICE AND DISCLAIMER}
_{Investing Media Solutions, LLC ("IMS"), the owner of this website (the "Website"), cannot guarantee the accuracy or completeness of the information contained in any article, email, newsletter, or other publication posted on or viewed in connection with this website (the "Publications"). The author or authors of those Publications are solely responsible for their contents. IMS has not done any research or due diligence into the markets, industries, or companies which may appear or be mentioned in the Publications.}_{IMS will NOT be liable for any loss or damage caused by a reader's reliance on information posted on the Website or contained in the Publications.}

_{FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE.}
_{This Website and the Publications are for educational and informational purposes only. This Website and the Publications do not purport to be a complete analysis of any company's financial position. This Website, the Publications or any statements made in the Publications are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual.}_{This Website or the statements made in the Publications should NOT be relied upon for purposes of transacting in any securities posted on the Website or mentioned in the Publications, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security posted on this Website or mentioned in any Publications.}

_{SUBSTANTIAL RISK IN INVESTMENT.}
_{Any individual who chooses to invest in any securities including those mentioned in the Publications should do so with caution.}_{Investing or transacting in securities involves substantial risk; you may lose some, all, or possibly more than your original investment.}_{Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional.}

_{NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER}
_{Neither IMS nor any of its respective owners or employees are registered or licensed as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization.}

_{To more fully understand our Website, please review our full disclaimer located at:}_{https://thecheapinvestor.com/disclaimer/}

_{At The Cheap Investor, it's our mission to create and provide a community that helps you invest and understand stocks. When TheCheapInvestor was established, we wanted to make the community an inclusive place where investors can come to get ahead! Not just help them with daily stock picks. The Cheap Investor are provided to you for information only and should not be considered as a stock or investment advisor. The Cheap Investor may make available certain information related to trading strategies and stock prices for educational and information purposes only; any information made available should not be construed as an endorsement, recommendation, or sponsorship of any company or security. By visiting this site or using the training materials, you acknowledge and agree that any reliance upon the content or data available through The Cheap Investor is at your own sole risk. You are strongly advised to use your own judgment, research, and consult a professional advisor.}

_{Over the years, and with thousands of followers that use our stock picks daily, we promise to always aim to get better at what we do every single day! In addition, our primary focus is on our communication with you. It's really important to us that every time you come to us, you end up leaving with the help you came for to take your investment portfolio to new levels.}

_{We particularly appreciate when our following provides feedback via testimonials, reviews, and comments left on our site or social media accounts. Because with that feedback, we can use it to make your next visit to our site even better than the last!}

_{Since we put so much effort into the relationship with you, we hope that any investment in us is exactly the way you hoped it would be. Because by choosing to go with}_{https://TheCheapInvestor.com/}_{, it's our promise that we provide a community you will come back to over and over again.}

_{Now, as much as we care about making investors more successful, we also care about your privacy. TheCheapInvestor is owned and operated by}_{TheCheapInvestor}_website.

_{We're committed to the right to your privacy and strive to provide a safe and secure user experience. Our Privacy Policy explains how we collect, store and use personal information, provided by you on our website.}

_{What Information Do We Collect?}

_{When you visit our Web site you may provide us with two types of information: personal information you knowingly choose to disclose that is collected on an individual basis and Web site use information collected on an aggregate basis as you and others browse our Web site.}

_{For example, you may need to provide the following information: • Name • Website URL information • Email address • Home and business phone number}

_{In addition to providing the foregoing information, if you choose to correspond further with us through email, we may retain the content of your email messages together with your email address and our responses. We provide the same protections for these electronic communications that we employ in the maintenance of information received by mail and telephone. It also explains important information that ensures we won't abuse the information that you provide to us in good faith. By accessing and using our website, you can trust that what you want to be kept private, will be kept private. If at any time, you would like to read our Privacy Policy and get a better understanding of your rights and liabilities under the law.}

_{Feel free to visit our site, find the privacy policy in the footer and read it. If there is something you are concerned about or wish to get more clarity on, please let us know by contacting us at}_{support@thecheapinvestor.com}_{. The Privacy Policy also informs you of how to notify us to stop using your personal information. If you wish to view our official policies, please visit our website}_{https://TheCheapInvestor.com/}

_{At The Cheap Investor, we are strongly committed to protecting your privacy and providing a safe & high-quality online experience for all of our visitors. We understand that you care about how the information you provide to us is used and shared. We have developed a Privacy Policy to inform you of our policies regarding the collection, use, and disclosure of information we receive from users of our website. The Cheap Investor operates the Website.}

_Our_{Privacy Policy}_{, along with our}_{Term & Conditions}_{, governs your use of this site. By using}_{https://TheCheapInvestor/}_{, or by accepting the Terms of Use (via opt-in, checkbox, pop-up, or clicking an email link confirming the same), you agree to be bound by our Terms & Conditions and our Privacy Policy. If you have provided personal, billing, or other voluntarily provided information, you may access, review, and make changes to it via instructions found on the Website or by emailing us at}_{support@thecheapinvestor.com}_{. To manage your receipt of marketing and non-transactional communications, you may unsubscribe by clicking the "unsubscribe" link located on the bottom of any marketing email. Emails related to the purchase or delivery of orders are provided automatically – Customers are not able to opt out of transactional emails. We will try to accommodate any requests related to the management of Personal Information in a timely manner. However, it is not always possible to completely remove or modify information in our databases (for example, if we have a legal obligation to keep it for certain timeframes, for example). If you have any questions, simply reply to this email or visit our website to view our official policies.}

Update your email preferences or unsubscribe here

203 N La Salle Suite 2100
Chicago , Illinois 60601, United States

sport football

Jumat, 03 April 2026

A setup we’re watching for Monday